Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, et al. Clin Cancer Res 2021;27:6106-6114.

Read + Share

Amedeo Smart

Independent Medical Education

van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, et al. Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. Clin Cancer Res 2021;27:6106-6114.
PMID: 34475104